Kenneth Duncan

Kenneth Duncan joined Accent in January 2020 as Vice President of Chemistry, bringing more than 18 years of biotech drug discovery experience. Prior to joining Accent, Kenneth served as Vice President of Medicinal Chemistry at Epizyme where he was a co-inventor of TAZVERIKTM, an EZH2 inhibitor, and the lead inventor of the first PRMT5 inhibitor, currently in phase 2 clinical trials. Previously, he worked with a number of biotech firms including Antisoma, Xanthus Pharmaceuticals, Infinity and Cyclacel on a range of oncology and non-oncology indications. Kenneth received his B.Sc. in Pure and Applied Chemistry from the University of Strathclyde in Glasgow, Scotland and remained there to complete his Ph.D. Studies with Professor Colin Suckling.